The kidney transplants for the 20 patients are working just as well as kidneys transplanted from donors without hepatitis C, suggesting the infection did not harm transplant quality, the researchers say.
Penn Medicine launched a clinical trial in 2016 to test how transplanting kidneys from donors with hepatitis C affected patients on the kidney transplant waitlist who do not have the virus. These patients would choose to receive these otherwise unused organs. Recipients then received an antiviral therapy to treat the virus after transplantation.
The trial included 12-month hepatitis C treatment outcomes in 10 patients and six-month outcomes in 10 other patients. All the patients received a lifesaving kidney transplant, were cured of their contracted hepatitis C and reported good quality of life after their transplants.
“This study, and the results, are good news for those in need of a transplant, particularly those patients who were facing tremendous wait times — often five, seven, even 10 years — and who were spending so much of their daily lives on dialysis,” said researcher Peter Reese, MD. “While larger, longer term studies are important to confirm these results, we can confidently say that hospitals nationwide could perform hundreds or thousands more transplants if we increased our acceptance of organs from donors with hepatitis C.”
More articles on clinical leadership and infection control:
Rabies-infected bat found in Texas hospital ER
Bacterial contamination of 6 frequently touched hospital objects
Phased approach encourages adoption of antibiotic stewardship efforts
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.